Earlier this month, WPAHS recorded a net loss of $19.8 million in the third quarter of its 2012 fiscal year, and in the nine months ended March 31, 2012, WPAHS has lost $75.7 million.
S&P analysts also said the health system’s less-than-desirable financial profile could have led to an even lower rating, but remaining in the “B” category reflects the increased likelihood and benefits of WPAHS merging with health insurer Highmark.
In a statement, WPAHS officials said S&P’s downgrade was “extremely disappointing and oddly timed in light of the recent progress” it was making, such as the reopening of West Penn Hospital’s emergency department and ongoing support from Highmark.
All three major credit rating agencies have downgraded WPAHS’ debt since November. Fitch Ratings downgraded WPAHS’ bonds to B+ from BB-, while Moody’s Investors Service’s ratings for the health system went to Caa1 from B2.
More Articles on West Penn Allegheny Health System:
Payor-Provider Integration: Anatomy of the Highmark-West Penn Deal
West Penn Loses Another $19.8M in Most Recent Quarter
West Penn Allegheny Claims UPMC Bribed Physicians to Leave
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
